Nab-paclitaxel in the treatment of metastatic breast cancer: A comprehensive review

Expert Review of Clinical Pharmacology

Volumn 4, Issue 3, 2011, Pages 329-334

  Montero, Alberto J ^a   Adams, Betsy ^b   Diaz Montero, C Marcela ^a   Glück, Stefan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

metastatic breast cancer; nab paclitaxel; taxanes

Indexed keywords

ALBUMIN; BEVACIZUMAB; DOCETAXEL; GEMCITABINE; NANOPARTICLE; PACLITAXEL; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BREAST CANCER; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; COMBINATION CHEMOTHERAPY; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PARTICLE SIZE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; PROGRESSION FREE SURVIVAL; REVIEW; SENSORY NEUROPATHY; TREATMENT RESPONSE;

ALBUMINS; ANIMALS; BREAST NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; NEOPLASM METASTASIS; PACLITAXEL; TREATMENT OUTCOME;

EID: 79955949716     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.7     Document Type: Review

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J. Natl Cancer Inst. 101, 1174-1181 (2009).
3. Robinson DM, Keating GM. Albumin-bound paclitaxel: in metastatic breast cancer. Drugs 66, 941-948 (2006). (Pubitemid 43847372)
4. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst. 83, 288-291 (1991).
5. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol. Oncol. Clin. North Am. 21, 257-272 (2007). (Pubitemid 46754731)
6. Jones SE, Erban J, Overmoyer B et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23, 5542-5551 (2005).
7. Seidman AD, Berry D, Cirrincione C et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol. 26, 1642-1649 (2008).
8. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358, 1663-1671 (2008). (Pubitemid 351549913)
9. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br. J. Cancer 93, 293-301 (2005). (Pubitemid 43080031)
10. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J. Clin. Oncol. 26, 1980-1986 (2008).
11. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J. Clin. Oncol. 26, 3950-3957 (2008).
12. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (naβpaclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).Ann. Oncol. 20, 449-453 (2009).
13. Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin. Breast Cancer 6, 361-364 (2005). (Pubitemid 41715700)
14. Lobo C, Lopes G, Silva O, Glck S. Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed. Pharmacother. 61, 531-533 (2007). (Pubitemid 47570079)
15. Gudena V, Montero AJ, Glck S. Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther. Clin. Risk Manag. 4(6), 1157-1164 (2008).
16. Brouwer E, Verweij J, De Bruijn P et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab. Dispos. 28, 1141-1145 (2000).
17. Taxol®, package insert. Bristol-Myers Squibb Company, Princeton, NJ, USA.
18. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598 (2001). (Pubitemid 32778603)
19. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044 (2002). (Pubitemid 34517637)
20. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317-1324 (2006). (Pubitemid 43342524)
21. Teng XY, Guan ZZ, Yao ZW et al. [A tolerability study of a cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor]. Ai Zheng 23, 1431-1436 (2004).
22. Nyman DW, Campbell KJ, Hersh E et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23, 7785-7793 (2005). (Pubitemid 46657375)
23. Stinchcombe TE, Socinski MA, Lee CB et al. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J. Thorac. Oncol. 3, 521-526 (2008). (Pubitemid 351630281)
24. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005). (Pubitemid 46657376)
25. Gradishar WJ, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with naβpaclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 27, 3611-3619 (2009).
26. Blum JL, Savin MA, Edelman G et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer 7, 850-856 (2007).
27. Ibrahim NK, Samuels B, Page R et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23, 6019-6026 (2005).
28. Lobo C, Lopes G, Glck S et al. Final results of a Phase II study of naβpaclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res. Treat. 123(2), 427-435 (2010).
29. Abraxane®, package insert. Abraxis BioScience, Inc., Los Angeles, CA, USA.